Fig. 2

Mutation status of TGFBR2, RHOA, and PREX2 in baseline ctDNA influenced the PFS of immunotherapy. a Summary of TGFBR2 mutations (P129Afs*3 and E269* were truncating mutations which could not displayed in the three-dimensional structure of the protein). b PFS analysis for TGFBR2 mutations in baseline plasma ctDNA. c Summary of RHOA mutations. d PFS analysis for RHOA mutations in baseline plasma ctDNA. e Summary of PREX2 mutations. f PFS analysis for PREX2 mutations in baseline plasma ctDNA